From Friday, June 7, until Tuesday, June 11th, the biggest diabetes conference of the year is taking place in San Francisco, California – the American Diabetes Association’s 79th Annual Scientific Sessions (#ADA2019). This annual meeting brings together researchers, healthcare providers, diabetes technology companies and many more from around the globe.
In these five days, there will be over 2,000 original research presentations and more than 180 sessions covering the latest advancements in research, treatment, and care for people living with diabetes. That’s a lot of news to take in! Beyond Type 1 is doing the hard work for you, and we’ll be reporting live from ADA 2019 – check back here for the most important and groundbreaking news coming out of the 79th Scientific Sessions, updated regularly over the course of the conference, and be sure to follow us on Twitter for live updates.
Some of the most exciting study results and announcements we’re looking forward to during the conference including:
The results of a pivotal trial of Tandem’s Control-IQ hybrid Closed-Loop study with the Dexcom G6. This will be the 2nd Closed-Loop study presented at ADA, and first since Medtronic 670G in 2016.
A landmark symposium on ‘Making Insulin Affordable’ featuring perspectives from manufacturers, pharmacy benefit managers (PBM), health plans, and JDRF’s Aaron Kowalski.
The potential FDA approval of the GVoke HypoPen from Xeris Pharmaceuticals. The shelf-stable liquid glucagon rescue pen will be groundbreaking for the treatment of hypoglycemia
Ahead of the official start of ADA 2019, T1D Exchange and DreaMed Diabetes announced a partnership to optimize insulin treatment plans in clinics • READ MORE
This page was last updated at 4:07pm PT June 9, 2019.
Editor’s Note: this article will be updated regularly with breaking news and announcements during the course of the ADA Scientific Sessions Conference. Check back often! Follow along on twitter at #ADA2019
TrialNet announced a breakthrough in Type 1 diabetes prevention: the TrialNet Teplizumab Prevention Study focused on relatives of people with Type 1 diabetes whose lifetime risk of developing T1D was thought to be 100%. During the trial, 72% of people in the control group receiving placebos developed Type 1 diabetes, compared to only 43% of those receiving teplizumab.
New, evidence-based recommendations for time-in-range targets have been determined by an international panel of diabetes experts striving for accurate parameters for CGM blood glucose level goals in both research and clinical settings. While the panel explains that CGM-based targets must be personalized to meet the needs of each individual, there is a general consensus on recommendations based on data from large pre-CGM clinical trials, CGM randomized controlled trials and expert opinion.
Tidepool announced that they have partnered with Dexcom as first iCGM partner for the Tidepool Loop project, as well as Medtronic, which joins Insulet as a pump partner. Tidepool is working to build and support an FDA-regulated version of Loop that will work with commercially available insulin pumps and CGMs. Both announcements were made at #DData19. Further coverage coming soon!
Editor’s Note: This article will be updated regularly with breaking news and announcements during the course of the ADA Scientific Sessions Conference. Check back often! Follow along on Twitter at #ADA2019
The results for the REWIND trial showed dulaglutide reduced cardiovascular events and kidney problems in older and middle-aged adults with Type 2 diabetes. The 5-year study evaluated more than 9,900 people over the globe – 6 continents and 24 countries – demonstrated a 12 percent reduction in CV events like heart attack and stroke in both men and women, with or without previous cardiovascular disease. The drug also reduced the development of kidney disease by 15 percent.
New, evidence-based recommendations for time-in-range targets have been determined by an international panel of diabetes experts striving for accurate parameters for CGM blood glucose level goals in both research and clinical settings. While the panel explains that CGM-based targets must be personalized to meet the needs of each individual, there is a general consensus on recommendations based on data from large pre-CGM clinical trials, CGM randomized controlled trials and expert opinion.
Ahead of the official start of ADA 2019, the American Diabetes Association made important changes to its 2019 Standards of Care for diabetic nephropathy based on the results of the CREDENCE (Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy) trial. Results showed the risk of end-stage renal disease, doubling of serum creatinine, and death from renal causes lowered by 34 percent after treatment with SGL2 inhibitor canagliflozin. The ADA’s updates for clinicians include changes to the frequency of assessing urinary albumin and estimated glomerular filtration rate; the time at which T2D patients with nephropathy should be treated with an SGLT2 inhibitor; the use of GLP-1s to reduce the risk of cardiovascular events, and removal of previous recommendations for microvascular complications and foot care.
I’m excited about Lilly’s URLi. I really like FIASP. I’m using it with my X2, but have to dilute it 80/20 with Humalog or Humalog diluent to get it working reliably. I’d love to have another option. The two URLi clinical trials used pumps so that’s encouraging.
In a study comparing it with Fiasp for injection, URLi was superior. Don’t know if that advantage carries over to pumps.
